Kalaris Therapeutics (KLRS) reported financial results for the second quarter ended June 30, 2026, including a net loss of $11.5 million, compared with a net loss of $11.4 million in the prior-year quarter.
The company said patient dosing is ongoing in its Phase 1b/2 study of TH103 for neovascular age-related macular degeneration, with preliminary data expected in the first half of 2027. Kalaris reported $93.5 million in cash, cash equivalents and marketable securities as of June 30, 2026, which it expects to fund operations into the fourth quarter of 2027.
- Net loss per share, basic and diluted, was $0.48 for the quarter ended June 30, 2026.
- Research and development expenses were $9.0 million, compared with $8.4 million a year earlier.
- General and administrative expenses were $3.4 million, compared with $3.8 million a year earlier.
- Potential Phase 3 clinical trials for TH103 remain on track for initiation by year-end 2027.
- Kalaris recently hired Liisa Bayko as chief financial officer and appointed Laurie Keating to its board of directors.
$KLRS Insider Trading Activity
$KLRS insiders have traded $KLRS stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $KLRS stock by insiders over the last 6 months:
- SRINIVAS AKKARAJU purchased 244,300 shares for an estimated $1,179,969
- BRETT R HAGEN (Chief Accounting Officer) sold 1,915 shares for an estimated $12,868
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$KLRS Hedge Fund Activity
We have seen 27 institutional investors add shares of $KLRS stock to their portfolio, and 16 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PROPEL BIO MANAGEMENT, LLC added 253,718 shares (+603.3%) to their portfolio in Q1 2026, for an estimated $1,463,952
- ALYESKA INVESTMENT GROUP, L.P. added 169,136 shares (+41.9%) to their portfolio in Q1 2026, for an estimated $975,914
- SIMPLIFY ASSET MANAGEMENT INC. removed 87,426 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $355,823
- REDMILE GROUP, LLC removed 82,955 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $478,650
- GOLDMAN SACHS GROUP INC added 76,200 shares (+222.1%) to their portfolio in Q1 2026, for an estimated $439,673
- MILLENNIUM MANAGEMENT LLC added 59,534 shares (+inf%) to their portfolio in Q1 2026, for an estimated $343,511
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 39,828 shares (+309.8%) to their portfolio in Q1 2026, for an estimated $229,807
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
